IMP321
Phase 1Biologic
IMP321 is one of 157 biologic programs targeting Metastatic Melanoma. It is currently in Phase 1.
4
Indications
7
Total Trials
1
Active Trials
156
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
947 competitors in Melanoma
#DrugCompanyPhaseTrials
1Single Dose of
Boehringer IngelheimPhase 3
Investigator's Choice
PfizerPhase 3
HBI-8000
HHUYABIO International, LLC.
Phase 3
Tumor Necrosis Factor
NNational Cancer Institute (NCI)
Phase 3
Zelboraf
CConrado Roberto Hoffmann Filho
Preclinical
GM2-KLH Vaccine
EEuropean Organisation for Research and Treatment of Cancer - EORTC
Phase 3
Intron a
Merck & Co.Preclinical
Opdualag
Bristol-Myers SquibbPreclinical
IO102-IO103
IIO Biotech
Phase 3
BCD-201
BBiocad
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Breast Carcinoma2 trials
Melanoma1 trial
Immunization of Disease-Free Melanoma Patients With Different HLA-A2 Peptides
Terminated·CCliniques universitaires Saint-Luc- Université Catholique de Louvain·Phase 1/2·NCT00365937·19 enrolled
Advanced Stage1 trial
Feasibility and Safety of IMP321 (Eftilagimod Alpha) for Advanced Stage Solid Tumors
Active, not recruiting·IInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest·Phase 1·NCT03252938·83 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for IMP321. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 1[1]
- Company
- IImmutep S.A.S.